

Supporting Information

A strategy for high radioprotective activity by the assembly of PprI protein with a ROS-sensitive polymeric carrier

Huijun Zhang^a, Qian Yuan^a, Suyi Cai^a, Yushuo Zhang^a, Meiyun Xu^a, Liangju Kuang^b, Daoben Hua^{a,c}*

^a State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Suzhou 215123, China

^b Schepens Eye Research Institute at Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, USA

^c Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou 215123, China

Table of contents

Characterization methods.....	S-2
Synthesis of PEG-CP ₅ K-NH ₂	S-2
Synthesis of PEG-CP ₅ K-NHS.....	S-2
Entrapment efficiency of PprI protein.....	S-2
Statistical analysis	S-3
Scheme S1.....	S-3
Figure S1.....	S-4
Figure S2.....	S-4
Figure S3.....	S-5
Reference.....	S-5

1. Characterization methods

¹H nuclear magnetic resonance (¹H NMR) spectra were taken by a Varian INVOA-400 instrument operated at 400 MHz. Fourier transform infrared (FT-IR) spectra were obtained on a Varian-1000 spectrometer; Scanning electron microscopy (SEM) images were obtained by a Hitachi S-4700 microscope working at an accelerating voltage (15 kV). Malvern Zetasizer with irradiation (He-Ne laser, 632.8 nm) was used to determine Zeta potential and Z-average size distribution of the nanoparticles. Absorbance in CCK-8 was measured at 570 nm with a Synergy 2 microplate reader (BioTek, USA). Blood samples were collected and analyzed by CELL-DYN 3700 blood cell analyzer (Abbott, Chicago).

2. Synthesis of PEG-CP₅K-NH₂

A typical procedure was described as follows¹: A degassed solution of triethyl amine (Et₃N) (0.352 mM, 0.048 mL) in a methanol (10 mL) and acetonitrile (10 mL) were added to a previously dried flask containing mPEG₁₁₃-MAL (0.16 mM, 0.8 g) and peptide (0.24 mM, 186 mg), then stir at room temperature (RT) for 24 h. Purify the reaction mixture through dialysis against methanol using 2k MW cutoff tubing for 24 h to acquire purified PEG-CP₅K-NH₂.

3. Synthesis of PEG-CP₅K-NHS

A typical procedure was described as follows²: a previously degassed solution of Et₃N (16.19 μg/mL, 0.024 mL) in DMF and anhydrous methanol mixture (1 : 1 ratio, 20 mL) were added to a dried, degassed flask containing PEG₁₁₃-CP₅K-NH₂ (0.08 mM, 0.462 g) and NHS (0.2 mM, 0.0624 g). The contents were purged with argon for 20 min to eliminate the dissolved oxygen, and then stir at room temperature for 48 h. The reaction mixture was precipitated by cold diethyl ether for three times, and the product was dried under vacuum at room temperature. The structure of PEG-CP₅K-NHS was characterized by ¹H NMR spectrum (Figure S1).


4. Entrapment efficiency of PprI protein

In order to evaluate the entrapment efficiency (EE) of PprI protein by CS-CP₅K-PEG, the Bradford assay was employed to quantify unpacked protein concentration after centrifugation using a 100kD ultrafiltration device (Millipore Centrifugal Filter Units). The Bradford Protein Assay Kit was purchased from Shanghai Yuanye Biotechnology Co. LTD., and the assay was conducted following the manufacturer's instructions^{3, 4} (<https://www.thermofisher.com/order/catalog/product/23200?SID=srch-srp-23200>).

The concentration of protein was determined according to the standard curve at 595 nm (Figure S2, Electronic Supplementary Information). On the basis of the assessment of concentration of unpacked PprI protein (C_1) and initial PprI protein (C_0), PprI protein entrapment efficiency (EE) was estimated as $EE = (C_0 - C_1)/C_0 \times 100\%$.

5. Statistical analysis

Results were expressed as means \pm standard deviations (SD). The data was analyzed using paired analysis of variance on SPSS 16.0 and the group means were compared by LSD Test. $P < 0.05$ was considered significant.



Scheme S1. Synthesis pathway of CS-CP₅K-PEG.




Figure S1. ¹H NMR spectra of (A) mPEG₁₁₃-MAL, (B) PEG-CP₅K-NH₂, and (C) PEG-CP₅K-NHS (400 M, CDCl₃). * indicates the signals from reactive hydrogen or grease. (In comparison with mPEG₁₁₃-MAL, the disappearance of maleimide peak at 6.75 ppm and the characteristic peaks appears at 2.11 ppm (CP₅K) for PEG-CP₅K-NH₂, indicating that peptide CP₅K was conjugated to mPEG-MAL^{1, 5}. The characteristic peak to NHS at 2.31 ppm suggested the conjugation of NHS to PEG-CP₅K-NH₂⁶)




Figure S2. The Bradford protein assay standard curve ($\lambda_{\text{max}} = 595 \text{ nm}$).




Figure S3. FT-IR spectra of (a) mPEG₁₁₃-MAL, (b) PEG-CP₅K-NH₂, (c) PEG-CP₅K-NHS and (d) CS-CP₅K-PEG.

Reference

1. Gupta, M. K.; Lee, S. H.; Crowder, S. W.; Wang, X.; Hofmeister, L. H.; Nelson, C. E.; Bellan, L. M.; Duvall, C. L.; Sung, H.-J., Oligoproline-derived nanocarrier for dual stimuli-responsive gene delivery. *Journal of Materials Chemistry B* **2015**, *3*, 7271-7280.
2. Zangoli, M.; Di Maria, F.; Zucchetti, E.; Bossio, C.; Antognazza, M. R.; Lanzani, G.; Mazzaro, R.; Corticelli, F.; Baroncini, M.; Barbarella, G., Engineering thiophene-based nanoparticles to induce phototransduction in live cells under illumination. *Nanoscale* **2017**, *9*, 9202-9209.
3. Mistry, H. D.; Bramham, K.; Weston, A. J.; Ward, M. A.; Thompson, A. J.; Chappell, L. C., Urine protein concentration estimation for biomarker discovery. *Pregnancy hypertension* **2013**, *3*, 211-4.
4. Li, M.; Sun, L.; Luo, Y.; Xie, C.; Pang, Y.; Li, Y., High-mobility group box 1 released from astrocytes promotes the proliferation of cultured neural stem/progenitor cells. *International journal of molecular medicine* **2014**, *34*, 705-14.
5. Ding, J.; Shi, F.; Xiao, C.; Lin, L.; Chen, L.; He, C.; Zhuang, X.; Chen, X., One-step preparation of reduction-responsive poly(ethylene glycol)-poly (amino acid)s nanogels as efficient intracellular drug delivery platforms. *Polymer Chemistry* **2011**, *2*, 2857-2864.
6. Casettari, L.; Vllasaliu, D.; Mantovani, G.; Howdle, S. M.; Stolnik, S.; Illum, L., Effect of PEGylation on the toxicity and permeability enhancement of chitosan. *Biomacromolecules* **2010**, *11*, 2854-2865.